The UC Davis/NIH NeuroMab Facility is a national monoclonal antibody-generating resource funded by the National Institutes of Health (NIH). The mission of the UC Davis/NIH NeuroMab Facility is to provide a unique neuroscience-based approach to generating mouse monoclonal antibodies optimized for use in mammalian brain (NeuroMabs). NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the UC Davis/NIH NeuroMab Facility screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e., NeuroMabs): for immunohistochemical- based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks.
The UC Davis/NIH NeuroMab Facility was funded from 2005-2015 with a U24 cooperative grant from NINDS and NIMH, and is currently funded by a High Impact Neuroscience Research Resource Grant (R24). The overall goal of the facility is to generate a library of novel, highly-validated NeuroMabs against neuronal proteins. These NeuroMabs are then be produced on a large scale and made available to the neuroscience research community on an inexpensive basis as tissue culture supernatants or purified immunoglobulin by our distribution contractor Antibodies Incorporated. To see the catalog of available antibodies go here.
The UC Davis/NIH NeuroMab Facility is also accepting suggestions as to potential targets. Requestors should supply the UC Davis/NIH NeuroMab Facility with a scientific justification as to the biological importance of the target molecule, the importance of these reagents to the national neuroscience community, and the availability and suitability of existing polyclonal and/or monoclonal antibodies. Also include a list of reagents (synthetic peptides, fusions proteins, full-length cDNAs for transfection in mammalian cells, samples from knockout mice) that will be made available to the UC Davis/NIH NeuroMab Facility staff to facilitate the development and characterization of these NeuroMabs. Submit this information to NeuroMab here. The UC Davis/NIH NeuroMab Facility advisory board, acting in concert with NIH program officials, will then prioritize the request in the UC Davis/NIH NeuroMab Facility queue. Note that all hybridomas and mAbs developed by the UC Davis/NIH NeuroMab Facility are the property of the Regents of the University of California.
The UC Davis/NIH NeuroMab Facility serves as a resource to the entire neuroscience community by providing high quality reagents that will serve as critical links between information emerging from genomic efforts and future proteomic approaches to brain function. Moreover, the unique neuroscience-based approach that the UC Davis/NIH NeuroMab Facility uses will yield reliable antibodies that might not otherwise be available, and the comprehensive biochemical and immunohistochemical verification will save countless investigators the time, money and effort of attempting to use expensive yet suboptimal reagents in their research.
UC Davis makes no warranties, either expressed or implied, concerning the accuracy, completeness, reliability, or suitability of the information contained on these Web pages or of the security or privacy of any information collected by these Web pages. All views expressed in the Web site are those of the author and not UC Davis.